Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis.

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Transactions of The Royal Society of Tropical Medicine and Hygiene Pub Date : 2025-03-07 DOI:10.1093/trstmh/trae095

João Pedro Sarcinelli Chagas, Juliana Ribeiro de Oliveira, Vinicius Andreata Brandão, Ana Paula Brandão Bellucio, João Victor de Azevedo Dutra, Julia Ramos Dutra, Crispim Cerutti

{"title":"Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis.","authors":"João Pedro Sarcinelli Chagas, Juliana Ribeiro de Oliveira, Vinicius Andreata Brandão, Ana Paula Brandão Bellucio, João Victor de Azevedo Dutra, Julia Ramos Dutra, Crispim Cerutti","doi":"10.1093/trstmh/trae095","DOIUrl":null,"url":null,"abstract":"Background: Considering the potential antiviral and immunomodulatory properties of imatinib, this drug has been investigated in several studies as a potential treatment option for severe cases of COVID-19, given that treatment modalities available remain limited.Objectives: To evaluate the benefits or otherwise of imatinib for COVID-19 in severely ill patients, we performed a systematic review of studies that tested the efficacy and the safety of imatinib for COVID-19 and executed a meta-analysis.Methods: We searched Medline, Embase and Cochrane with the following search terms: 'coronavirus', 'SARS-Cov2', 'covid', 'covid-19' and 'imatinib'. The latest search date was November 2023. We used Cochrane Collaboration's tool to assess bias in randomized trials.Results: We included three randomized controlled trials with 561 participants. A total of 276 patients received imatinib and 285 received placebo. The mortality results showed no statistically significant differences between imatinib and controls (RR 0.61; 95% CI 0.37 to 1.01; p=0.06). There was no significant difference in length of hospital stay or severe adverse events occurring between groups.Conclusions: Current evidence suggests that the potential benefits of imatinib should be further evaluated in randomized controlled trials in patients hospitalized for COVID-19.","PeriodicalId":23218,"journal":{"name":"Transactions of The Royal Society of Tropical Medicine and Hygiene","volume":" ","pages":"203-209"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transactions of The Royal Society of Tropical Medicine and Hygiene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/trstmh/trae095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Considering the potential antiviral and immunomodulatory properties of imatinib, this drug has been investigated in several studies as a potential treatment option for severe cases of COVID-19, given that treatment modalities available remain limited.

Objectives: To evaluate the benefits or otherwise of imatinib for COVID-19 in severely ill patients, we performed a systematic review of studies that tested the efficacy and the safety of imatinib for COVID-19 and executed a meta-analysis.

Methods: We searched Medline, Embase and Cochrane with the following search terms: 'coronavirus', 'SARS-Cov2', 'covid', 'covid-19' and 'imatinib'. The latest search date was November 2023. We used Cochrane Collaboration's tool to assess bias in randomized trials.

Results: We included three randomized controlled trials with 561 participants. A total of 276 patients received imatinib and 285 received placebo. The mortality results showed no statistically significant differences between imatinib and controls (RR 0.61; 95% CI 0.37 to 1.01; p=0.06). There was no significant difference in length of hospital stay or severe adverse events occurring between groups.

Conclusions: Current evidence suggests that the potential benefits of imatinib should be further evaluated in randomized controlled trials in patients hospitalized for COVID-19.

查看原文本刊更多论文

评估伊马替尼在重症 COVID-19 中的应用：系统综述和荟萃分析。

背景：考虑到伊马替尼潜在的抗病毒和免疫调节特性，一些研究已将该药物作为COVID-19重症病例的潜在治疗方案进行了调查，因为现有的治疗方法仍然有限：为了评估伊马替尼治疗重症患者 COVID-19 的疗效，我们对伊马替尼治疗 COVID-19 的疗效和安全性进行了系统回顾，并进行了荟萃分析：我们使用以下检索词对 Medline、Embase 和 Cochrane 进行了检索：冠状病毒"、"SARS-Cov2"、"COVID"、"COVID-19 "和 "伊马替尼"。最新搜索日期为 2023 年 11 月。我们使用 Cochrane 协作组织的工具来评估随机试验的偏倚：我们纳入了三项随机对照试验，共有 561 名参与者。共有 276 名患者接受了伊马替尼治疗，285 名患者接受了安慰剂治疗。死亡率结果显示，伊马替尼与对照组之间没有显著的统计学差异（RR 0.61；95% CI 0.37至1.01；P=0.06）。两组患者的住院时间或发生的严重不良事件也无明显差异：目前的证据表明，应在随机对照试验中进一步评估伊马替尼对COVID-19住院患者的潜在益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transactions of The Royal Society of Tropical Medicine and Hygiene 医学-公共卫生、环境卫生与职业卫生

CiteScore

4.00

自引率

9.10%

发文量

115

审稿时长

4-8 weeks

期刊介绍： Transactions of the Royal Society of Tropical Medicine and Hygiene publishes authoritative and impactful original, peer-reviewed articles and reviews on all aspects of tropical medicine.